By: Dylan Sikes - AllPennyStocks.com News

Friday, November 11, 2016

The biotechnology sector has edged lower in trading today. Despite the pullback in trading today, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) is still up more than 9.5% since the election results earlier this week. The election of Donald Trump as the President has boosted the sector as Democrat Presidential candidate Hillary Clinton had been critical of the pricing policy practiced in the biotech sector. The sector has also benefited from the rally in the broader market.

The sector is also likely to get a boost from M&A activity, which is likely to increase as the uncertainty over the U.S. election is now over. Several catalysts involving major drug companies are also lined up in the next six months. Any positive news on this front could provide a further boost to the biotech sector.

GeoVax Labs Inc. (OTCQB:GOVX) is a Smyrna, Georgia-based clinical-stage biotechnology company. The company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The company’s platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. Its development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg and Lassa Fever), as well as for use in cancer immunotherapy.

GeoVax shares are gaining momentum after the company announced its financial results for the third quarter of 2016 and also provided an update on its pipeline. The company reported a net loss of $464,200, or $0.01 per share for the quarter, compared to a loss of $619,899 or $0.02 per share reported for the same period in the previous year. GOVX reported revenue of $440,106 for the quarter, compared to $93,130 reported for the same period in the previous year.

GOVX said that its most advanced program, a prophylactic vaccine for the Clade B subtype of HIV, has successfully completed Phase 1 and Phase 2a human clinical trials. The company said that its next human clinical trial of GeoVax's preventive HIV vaccine (GOVX-B11) - a Phase 1 trial, designated HVTN 114, will investigate the ability of late boosts to increase the antibody responses elicited by GOVX-B11. HVTN 114 will be conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Diseases (NIAID). HVTN has informed GeoVax that it expects this trial to commence in January 2017.

Although the biotech sector has edged lower in trading today, as mentioned above, shares of GeoVax are rallying. At last check, GOVX shares were trading 6.45% higher at $0.0586 on volume of 96,592, which is below the daily average volume of 265,268. Although today’s performance is strong, overall the mood is sour as the stock trades near its 52 week lows.

Copyright © 2016 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.